Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa
OX40-OX40L interaction is a key pathogenetic feature in HS, and patients with HS might benefit from combined TNF-α/OX40L blockade by SAR442970, which is currently investigated in a clinical phase 2 trial.
Authors
- Karen Heyninck (ORCID: https://orcid.org/0000-0002-4068-1344)
- Theresa-Charlotte Brembach
- Frank Nestle
- Yasmine M. Hijazi
- Deimantė Šimaitė
- Kerstin Wolk (ORCID: https://orcid.org/0000-0002-7689-4130)
- Clément Levin
- Markus Kohlmann
- Robert Sabat (ORCID: https://orcid.org/0000-0002-0198-940X)
- Sigrid Cornelis
- Thomas Leeuw
- Matthias Herrmann (ORCID: https://orcid.org/0000-0002-0736-6668)
- Peter Florian
- Heidi Rommelaere
- Thomas Kreutzberg
Institutions
- Sanofi (France) (FR)
- Humboldt-Universität zu Berlin (DE)
- Sanofi (Belgium) (BE)
- Sanofi (Germany) (DE)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.jacig.2025.100483
- Citations
- 8
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 16.04
Funders
- Sanofi-Aventis Deutschland